Effectiveness of Resmetirom in Treating Nonalcoholic Steatohepatitis
|
Reviewed & translated by Dat Tien Nguyen, B.A, ScM.
|
Posted on March 25th, 2024
|
As Vietnam experiences economic development, the incidence of nonalcoholic steatohepatitis cases is on the rise. However, there is currently no approved treatment for this condition. Resmetirom is a novel agent that activates the thyroid hormone receptor beta (THR-β) in the liver, thereby reactivating the crucial process of fatty acid β-oxidation to mitigate the risk of fibrosis. A study was conducted to evaluate the efficacy of Resmetirom in treating nonalcoholic steatohepatitis.
The phase 3 clinical trial enrolled 966 participants, with an average age of approximately 56 years and an average body mass index (BMI) of around 36. The prevalence of hypertension in the study cohort was approximately 78%, and around 71% had dyslipidemia. Liver stiffness, assessed using vibration-controlled transient elastography, revealed a mean measurement of about 13 kPa. Liver biopsy results showed that nearly two-thirds of the patients exhibited F3 fibrosis. Participants were randomly assigned to receive either Resmetirom or a placebo orally. Following a 52-week follow-up period, the researchers found that Resmetirom resolved NASH in approximately 28% of the participants, a significantly higher proportion than the 10% observed in the placebo group. Additionally, treatment with Resmetirom led to a reduction in low-density lipoprotein levels, with minimal differences in the incidence of adverse events between the two groups.
The phase 3 clinical trial enrolled 966 participants, with an average age of approximately 56 years and an average body mass index (BMI) of around 36. The prevalence of hypertension in the study cohort was approximately 78%, and around 71% had dyslipidemia. Liver stiffness, assessed using vibration-controlled transient elastography, revealed a mean measurement of about 13 kPa. Liver biopsy results showed that nearly two-thirds of the patients exhibited F3 fibrosis. Participants were randomly assigned to receive either Resmetirom or a placebo orally. Following a 52-week follow-up period, the researchers found that Resmetirom resolved NASH in approximately 28% of the participants, a significantly higher proportion than the 10% observed in the placebo group. Additionally, treatment with Resmetirom led to a reduction in low-density lipoprotein levels, with minimal differences in the incidence of adverse events between the two groups.